Head And Neck Cancer - Pipeline Review, H1 2018

  • ID: 4529327
  • Drug Pipelines
  • 1639 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • Bicycle Therapeutics Ltd
  • Etubics Corp
  • Incyte Corp
  • Moderna Therapeutics Inc
  • Profectus BioSciences Inc
  • MORE
Head And Neck Cancer - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer - Pipeline Review, H1 2018, provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape.

Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx). The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

Report Highlights:

This latest pipeline guide Head And Neck Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Head And Neck Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Head And Neck Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 21, 113, 120, 6, 75, 20 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 10, 8, 15, 4 and 1 molecules, respectively.

Head And Neck Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Head And Neck Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Head And Neck Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • Bicycle Therapeutics Ltd
  • Etubics Corp
  • Incyte Corp
  • Moderna Therapeutics Inc
  • Profectus BioSciences Inc
  • MORE
Introduction

Head And Neck Cancer - Overview

Head And Neck Cancer - Therapeutics Development

Head And Neck Cancer - Therapeutics Assessment

Head And Neck Cancer - Companies Involved in Therapeutics Development

Head And Neck Cancer - Drug Profiles

Head And Neck Cancer - Dormant Projects

Head And Neck Cancer - Discontinued Products

Head And Neck Cancer - Product Development Milestones

Appendix

List of Tables

Table 1: Number of Products under Development for Head And Neck Cancer, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Table 7: Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Table 8: Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Table 9: Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Table 10: Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Table 11: Number of Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Table 12: Number of Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Table 13: Number of Products under Development by Companies, H1 2018 (Contd..11), H1 2018

Table 14: Number of Products under Development by Companies, H1 2018 (Contd..12), H1 2018

Table 15: Number of Products under Development by Universities/Institutes, H1 2018

Table 16: Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Table 17: Products under Development by Companies, H1 2018

Table 18: Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 19: Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 20: Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Table 21: Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Table 22: Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Table 23: Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Table 24: Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Table 25: Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Table 26: Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Table 27: Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Table 28: Products under Development by Companies, H1 2018 (Contd..11), H1 2018

Table 29: Products under Development by Companies, H1 2018 (Contd..12), H1 2018

Table 30: Products under Development by Companies, H1 2018 (Contd..13), H1 2018

Table 31: Products under Development by Companies, H1 2018 (Contd..14), H1 2018

Table 32: Products under Development by Companies, H1 2018 (Contd..15), H1 2018

Table 33: Products under Development by Companies, H1 2018 (Contd..16), H1 2018

Table 34: Products under Development by Companies, H1 2018 (Contd..17), H1 2018

Table 35: Products under Development by Companies, H1 2018 (Contd..18), H1 2018

Table 36: Products under Development by Companies, H1 2018 (Contd..19), H1 2018

Table 37: Products under Development by Companies, H1 2018 (Contd..20), H1 2018

Table 38: Products under Development by Companies, H1 2018 (Contd..21), H1 2018

Table 39: Products under Development by Companies, H1 2018 (Contd..22), H1 2018

Table 40: Products under Development by Companies, H1 2018 (Contd..23), H1 2018

Table 41: Products under Development by Companies, H1 2018 (Contd..24), H1 2018

Table 42: Products under Development by Universities/Institutes, H1 2018

Table 43: Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Table 44: Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018

Table 45: Number of Products by Stage and Target, H1 2018

Table 46: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Table 47: Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Table 48: Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018

Table 49: Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018

Table 50: Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018

Table 51: Number of Products by Stage and Target, H1 2018 (Contd..6), H1 2018

Table 52: Number of Products by Stage and Target, H1 2018 (Contd..7), H1 2018

Table 53: Number of Products by Stage and Target, H1 2018 (Contd..8), H1 2018

Table 54: Number of Products by Stage and Mechanism of Action, H1 2018

Table 55: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Table 56: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018

Table 57: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018

Table 58: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018

Table 59: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018

Table 60: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..6), H1 2018

Table 61: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..7), H1 2018

Table 62: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..8), H1 2018

Table 63: Number of Products by Stage and Route of Administration, H1 2018

Table 64: Number of Products by Stage and Molecule Type, H1 2018

Table 65: Number of Products by Stage and Molecule Type, H1 2018 (Contd..1), H1 2018

Table 66: Head And Neck Cancer - Pipeline by 3SBio Inc, H1 2018

Table 67: Head And Neck Cancer - Pipeline by 4SC AG, H1 2018

Table 68: Head And Neck Cancer - Pipeline by AbbVie Inc, H1 2018

Table 69: Head And Neck Cancer - Pipeline by Abion Inc, H1 2018

Table 70: Head And Neck Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2018

List of Figures

Figure 1: Number of Products under Development for Head And Neck Cancer, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products under Development by Universities/Institutes, H1 2018

Figure 4: Number of Products by Top 10 Targets, H1 2018

Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018

Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Figure 10: Number of Products by Top 10 Molecule Types, H1 2018

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3SBio Inc
  • 4SC AG
  • AbbVie Inc
  • Abion Inc
  • Adaptimmune Therapeutics Plc
  • Admedus Ltd
  • Aduro BioTech Inc
  • Advaxis Inc
  • Advenchen Laboratories LLC
  • Affimed GmbH
  • Altor BioScience Corp
  • Ambrx Inc
  • amcure GmbH
  • Amgen Inc
  • arGEN-X BV
  • ArQule Inc
  • Array BioPharma Inc
  • Ascentage Pharma Group Corp Ltd
  • Aspyrian Therapeutics Inc
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Aurigene Discovery Technologies Ltd
  • AVEO Pharmaceuticals Inc
  • Bayer AG
  • BeiGene Ltd
  • Benitec Biopharma Ltd
  • Bexion Pharmaceuticals LLC
  • Bicycle Therapeutics Ltd
  • BioDiem Ltd
  • Biohaven Pharmaceutical Holding Company Ltd
  • Biomics Biotechnologies Co Ltd
  • Bionovis SA
  • BioNTech AG
  • Biothera Pharmaceutical Inc
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Co
  • CBT Pharmaceuticals Inc
  • CEL-SCI Corp
  • Celgene Corp
  • Cell Medica Ltd
  • Celldex Therapeutics Inc
  • Cellectar Biosciences Inc
  • Celprogen Inc
  • Checkpoint Therapeutics Inc
  • Corvus Pharmaceuticals Inc
  • Cotinga Pharmaceuticals Inc
  • Cristal Therapeutics BV
  • Curevac AG
  • Cyclacel Pharmaceuticals Inc
  • CytImmune Sciences Inc
  • CytomX Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Denceptor Therapeutics Ltd
  • DNJ Pharma Inc
  • Dynavax Technologies Corp
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Enzene Biosciences Ltd
  • Etubics Corp
  • Eureka Therapeutics Inc
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Formation Biologics Inc
  • Forty Seven Inc
  • Fujifilm Holdings Corporation
  • G&E Herbal Biotechnology Co Ltd
  • Galectin Therapeutics Inc
  • Genelux Corp
  • Genentech Inc
  • GeneSegues Inc
  • Genmab A/S
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Gliknik Inc
  • Glycotope GmbH
  • Hanmi Pharmaceuticals Co Ltd
  • Harbin Gloria Pharmaceuticals Co Ltd
  • Hookipa Biotech AG
  • Horizon Pharma Plc
  • Hutchison MediPharma Ltd
  • Idera Pharmaceuticals Inc
  • Ignyta Inc
  • Immatics Biotechnologies GmbH
  • Immunocore Ltd
  • Immunomedics Inc
  • Immunovaccine Inc
  • Immunovative Therapies Ltd
  • Immutep Ltd
  • Incyte Corp
  • Infinity Pharmaceuticals Inc
  • Innate Pharma SA
  • Inovio Pharmaceuticals Inc
  • InteRNA Technologies BV
  • Iovance Biotherapeutics Inc
  • IRX Therapeutics Inc
  • ISA Pharmaceuticals BV
  • ISU ABXIS Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu Kanion Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Jounce Therapeutics Inc
  • Juno Therapeutics Inc
  • Kite Pharma Inc
  • Kura Oncology Inc
  • Laboratoires Pierre Fabre SA
  • LATITUDE Pharmaceuticals Inc
  • Loxo Oncology Inc
  • Lycera Corp
  • Lytix Biopharma AS
  • Mabion SA
  • MacroGenics Inc
  • Madrigal Pharmaceuticals Inc.
  • Marsala Biotech Inc
  • Mateon Therapeutics Inc
  • MaxiVAX SA
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • Merrimack Pharmaceuticals Inc
  • Mersana Therapeutics Inc
  • Millennium Pharmaceuticals Inc
  • Mirati Therapeutics Inc
  • Moderna Therapeutics Inc
  • Molecular Partners AG
  • Molecular Templates Inc
  • Moleculin Biotech Inc
  • NanoCarrier Co Ltd
  • NantKwest Inc
  • Natco Pharma Ltd
  • NeoImmuneTech Inc
  • Neonc Technologies Inc
  • Neumedicines Inc
  • Novartis AG
  • Noxopharm Ltd
  • Oncobiologics Inc
  • Oncolys BioPharma Inc
  • Onconova Therapeutics Inc
  • Oncovir Inc
  • Ono Pharmaceutical Co Ltd
  • Otsuka Holdings Co Ltd
  • Oxford Vacmedix UK Ltd
  • PDS Biotechnology Corp
  • Pfizer Inc
  • Pharma Mar SA
  • Phosplatin Therapeutics LLC
  • Plexxikon Inc
  • PNP Therapeutics Inc
  • Profectus BioSciences Inc
  • Provectus Biopharmaceuticals Inc
  • PsiOxus Therapeutics Ltd
  • R Pharm
  • Regeneron Pharmaceuticals Inc
  • Reliance Life Sciences Pvt Ltd
  • Sareum Holdings Plc
  • Selecta Biosciences Inc
  • Shanghai Henlius Biotech Co Ltd
  • Shionogi & Co Ltd
  • Sierra Oncology Inc
  • Sillajen Biotherapeutics
  • Sinil Pharmaceutical Co Ltd
  • Soricimed Biopharma Inc
  • Sorrento Therapeutics Inc
  • Sound Pharmaceuticals Inc
  • Spherium Biomed SL
  • Sumitomo Dainippon Pharma Co Ltd
  • SuviCa Inc
  • SynCore Biotechnology Co Ltd
  • Systimmune Inc
  • Takis Srl
  • Tessa Therapeutics Pte Ltd
  • Theralase Technologies Inc
  • Theravectys SA
  • Tolero Pharmaceuticals Inc
  • Tosk Inc
  • Transgene SA
  • UbiVac LLC
  • Vaccibody AS
  • VasGene Therapeutics Inc
  • Vault Pharma Inc
  • Vaxeal Holding SA
  • Vectorite Biomedical Inc
  • Viracta Therapeutics Inc
  • Vyriad Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll